Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel and Capecitabine Plus Docetaxel in Metastatic Breast Cancer Patients in Egypt

Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2207
https://www.valueinhealthjournal.com/article/S1098-3015(14)04137-0/fulltext
Title : Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel and Capecitabine Plus Docetaxel in Metastatic Breast Cancer Patients in Egypt
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04137-0&doi=10.1016/j.jval.2014.08.2207
First page : A622
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1665
Categories :
Tags :
Regions :
ViH Article Tags :